Nordmark: a strong network
Our subsidiaries and cooperation partners complement our core expertise with specialised know-how. In development and implementation of new projects we work closely with our partners and use the professional synergies of this network for the benefit of our customers.
Your partner in the development and production of biological pharmaceuticals. BIBITEC is a contract manufacturer (CMO) for GMP-compliant active ingredient production using mammalian cells. We support you in the realisation of your project - from the initial idea to the finished medicinal product. BIBITEC has approval for active ingredient production including clinical phase III. As a wholly owned subsidiary of Nordmark Pharma GmbH we offer you a single point of contact for all aspects of your project. We cover the entire value chain with our cooperation partners — from process development to market supply.
Nordix Pharma Vertrieb GmbH is a 100%-owned subsidiary of Nordmark Pharma GmbH. Founded in December 2005, it is responsible for the distribution of Nordmark´s own brands (Pankreatan, Enzyorm f, Thrombophob) in Germany.
Norbitec GmbH was founded in 2003 as a joint venture. It is a company of the BIOCEUTICALS Arzneimittel AG, a holding company of STADA Arzneimittel AG and Nordmark Pharma GmbH. Its focus is on the production of erythropoietin (Epoetin zeta), a biotechnologically produced active substance for the treatment of anaemia.
Nordmark Biochemicals is a business unit of Nordmark Pharma GmbH specialising in the distribution of biochemicals. The main focus is on collagenases and other proteases that can be used for tissue dissociation in vitro for the isolation of a variety of cells. These cells have a variety of applications in research and clinical settings. Since 2002, Nordmark produces Collagenase NB products for research and clinical applications. Since 2018, Nordmark Biochemicals has combined product development, sales and customer service in one department directly at the production site.
Nordmark Biotech, the biotechnology division of Nordmark, specialises in the customised development and production of biopharmaceuticals from laboratory to production scale. With expertise in microbial fermentation and mammalian cell culture we cover the entire value chain from process development to market-ready products, including formulation and fill and finish. For the successful development of your product, Nordmark Biotech also offers analytical and regulatory support. Almost 90 years of excellence and commercial success make Nordmark your ideal partner for developing your ideas for the market.
In 2021 Nordmark has acquired majority shares of Akesion - a young biopharmaceutical company specialized in the development of novel and innovative therapeutics for the treatment of diseases with high unmet medical needs, thereby creating value for patients and investors. The company was founded in 2014 by an experienced management team in order to provide the commercial infrastructure for research activities.